Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMIT-1: IV Favipiravir and Ribavirin in CCHF
NCT05940545Phase 2Unknown
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of favipiravir in Crimean–Congo hemorrhagic fever (CCHF), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Safety and tolerability of multiple doses of IV Favipiravir alone and in combination with Ribavirin at Day 8. Status: unknown.
02
Drugs
favipiravir
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)
Beyond the preview
Go deeper on NCT05940545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940545.